Sanofi steps up with a $645M deal to partner with AstraZeneca on a late-stage RSV antibody
Pointing directly at a pivotal Phase III program, AstraZeneca has decided to partner with Sanofi on an experimental antibody for RSV.
The French pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
